Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94

Clinical and Experimental Metastasis

Volumn 33, Issue 5, 2016, Pages 461-473

  Sudhan, Dhivya R ^a   Rabaglino, Maria B ^c   Wood, Charles E ^b   Siemann, Dietmar W ^a,b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Angiogenesis; Breast cancer; Cathepsin L; KGP94

Indexed keywords

3 BROMOPHENYL 3 HYDROXYPHENYL KETONE THIOSEMICARBAZONE; ANGIOGENESIS INHIBITOR; CATHEPSIN L; CENTROSOME ASSOCIATED PROTEIN E; CYCLIN A; CYCLIN B; CYCLIN D; CYCLINE; KETONE; KINESIN 5; PROTEIN; SHORT HAIRPIN RNA; THIOSEMICARBAZONE; UNCLASSIFIED DRUG; KGP94; THIOSEMICARBAZONE DERIVATIVE; THIOUREA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DISTANT METASTASIS; DRUG EFFICACY; ENDOTHELIUM CELL; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPROUTING; TUMOR INVASION; UPREGULATION; ADULT; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL MOTION; DRUG EFFECTS; GENETICS; MICROMETASTASIS; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PREVENTION AND CONTROL; TUMOR CELL LINE; TUMOR RECURRENCE; UMBILICAL VEIN ENDOTHELIAL CELL;

ADULT; AGED; BREAST NEOPLASMS; CATHEPSIN L; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM MICROMETASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; THIOSEMICARBAZONES; THIOUREA;

EID: 84964048466     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-016-9790-1     Document Type: Article

References (59)

1. Siegel R et al (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29
2. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
3. Siemann DW (2011) The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev 37(1):63–74
4. Weidner N et al (1991) Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Engl J Med 324(1):1–8
5. Burden RE et al (2009) Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis. Clin Cancer Res 15(19):6042–6051
6. Lakka SS et al (2004) Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23(27):4681–4689
7. Chauhan SS, Goldstein LJ, Gottesman MM (1991) Expression of cathepsin L in human tumors. Cancer Res 51(5):1478–1481
8. Sudhan DR, Siemann DW (2015) Cathepsin L targeting in cancer treatment. Pharmacol Ther 155:105–116
9. Chapman HA, Riese RJ, Shi GP (1997) Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 59:63–88
10. Gottesman MM, Sobel ME (1980) Tumor promoters and Kirsten sarcoma virus increase synthesis of a secreted glycoprotein by regulating levels of translatable mRNA. Cell 19(2):449–455
11. Rabin MS, Doherty PJ, Gottesman MM (1986) The tumor promoter phorbol 12-myristate 13-acetate induces a program of altered gene expression similar to that induced by platelet-derived growth factor and transforming oncogenes. Proc Natl Acad Sci USA 83(2):357–360
12. Denhardt DT et al (1986) Close relationship of the major excreted protein of transformed murine fibroblasts to thiol-dependent cathepsins. Cancer Res 46(9):4590–4593
13. Jordans S et al (2009) Monitoring compartment-specific substrate cleavage by cathepsins B, K, L, and S at physiological pH and redox conditions. BMC Biochem 10:23
14. Novinec M, Lenarcic B, Turk B (2014) Cysteine cathepsin activity regulation by glycosaminoglycans. Biomed Res Int 2014:309718
15. Everts V et al (2006) Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Miner Res 21(9):1399–1408
16. Goretzki L et al (1992) Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. FEBS Lett 297(1–2):112–118
17. Ishidoh K, Kominami E (1995) Procathepsin L degrades extracellular matrix proteins in the presence of glycosaminoglycans in vitro. Biochem Biophys Res Commun 217(2):624–631
18. Laurent-Matha V et al (2006) Processing of human cathepsin D is independent of its catalytic function and auto-activation: involvement of cathepsins L and B. J Biochem 139(3):363–371
19. Mason RW et al (1986) Elastinolytic activity of human cathepsin L. Biochem J 233(3):925–927
20. Frade R et al (1998) Procathepsin-L, a proteinase that cleaves human C3 (the third component of complement), confers high tumorigenic and metastatic properties to human melanoma cells. Cancer Res 58(13):2733–2736
21. Gocheva V et al (2006) Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 20(5):543–556
22. Chavarria GE et al (2012) Initial evaluation of the antitumour activity of KGP94, a functionalized benzophenone thiosemicarbazone inhibitor of cathepsin L. Eur J Med Chem 58:568–572
23. Sudhan DR, Siemann DW (2013) Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells. Clin Exp Metastasis 30(7):891–902
24. Sudhan DR et al (2016) Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model. Int J Cancer 138:2665–2677
25. Kumar GD et al (2010) Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett 20(22):6610–6615
26. Gyorffy B et al (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123(3):725–731
27. Siemann DW et al (2009) Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474). Anticancer Res 29(6):1987–1992
28. Smyth GK (2005) Limma: linear models for microarray data, vol. 397–420. Springer, New York
29. de Hoon MJL, Imoto S, Nolan J, Miyano S (2004) Open source clustering software. Bioinform Appl Notes 20(9):1453–1454
30. Subramanian A et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545–15550
31. Shannon P et al (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13(11):2498–2504
32. Montojo J et al (2010) GeneMANIA Cytoscape plugin: fast gene function predictions on the desktop. Bioinformatics 26(22):2927–2928
33. Nishida Y et al (1995) Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA125 and CA72-4. Gynecol Oncol 56(3):357–361
34. Siewinski M et al (2004) Determination of cysteine peptidases-like activity and their inhibitors in the serum of patients with ovarian cancer treated by conventional chemotherapy and vitamin E. J Exp Ther Oncol 4(3):189–193
35. Svatek RS et al (2008) Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma. J Urol 179(2):478–484 discussion 84
36. Tumminello FM et al (1996) Cathepsin D, B and L circulating levels as prognostic markers of malignant progression. Anticancer Res 16(4B):2315–2319
37. van Hinsbergh VW, Koolwijk P (2008) Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc Res 78(2):203–212
38. Arnaoutova I, Kleinman HK (2010) In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. Nat Protoc 5(4):628–635
39. Zhang J et al (2010) Plasma cathepsin L and its related pro/antiangiogenic factors play useful roles in predicting rich coronary collaterals in patients with coronary heart disease. J Int Med Res 38(4):1389–1403
40. Sun J et al (2011) Cathepsin L activity is essential to elastase perfusion-induced abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol 31(11):2500–2508
41. Keerthivasan S et al (2007) Transcriptional upregulation of human cathepsin L by VEGF in glioblastoma cells. Gene 399(2):129–136
42. Jain M et al (2010) Cathepsins B and L in peripheral blood mononuclear cells of pediatric acute myeloid leukemia: potential poor prognostic markers. Ann Hematol 89(12):1223–1232
43. Samaiya M et al (2011) Epigenetic regulation of cathepsin L expression in chronic myeloid leukaemia. J Cell Mol Med 15(10):2189–2199
44. Tamada Y et al (2000) Involvement of cysteine proteases in bFGF-induced angiogenesis in guinea pig and rat cornea. J Ocul Pharmacol Ther 16(3):271–283
45. Chung JH et al (2011) Cathepsin L derived from skeletal muscle cells transfected with bFGF promotes endothelial cell migration. Exp Mol Med 43(4):179–188
46. Asanuma K et al (2002) Selective modulation of the secretion of proteinases and their inhibitors by growth factors in cultured differentiated podocytes. Kidney Int 62(3):822–831
47. Eilken HM, Adams RH (2010) Dynamics of endothelial cell behavior in sprouting angiogenesis. Curr Opin Cell Biol 22(5):617–625
48. Frade R, Rousselet N, Jean D (2008) Intratumoral gene delivery of anti-cathepsin L single-chain variable fragment by lentiviral vector inhibits tumor progression induced by human melanoma cells. Cancer Gene Ther 15(9):591–604
49. Dennemarker J et al (2010) Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis. Oncogene 29(11):1611–1621
50. Urbich C et al (2005) Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med 11(2):206–213
51. Handsley MM, Edwards DR (2005) Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 115(6):849–860
52. Rebbaa A et al (2009) The anti-angiogenic activity of NSITC, a specific cathepsin L inhibitor. Anticancer Res 29(11):4473–4481
53. Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14(2):163–176
54. Yu WH et al (2002) CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 16(3):307–323
55. Paez-Ribes M et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3):220–231
56. Cairns RA, Hill RP (2004) Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res 64(6):2054–2061
57. Keith B, Simon MC (2007) Hypoxia-inducible factors, stem cells, and cancer. Cell 129(3):465–472
58. Horsman MR, Siemann DW (2006) Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66(24):11520–11539
59. Siemann DW, Horsman MR (2015) Modulation of the tumor vasculature and oxygenation to improve therapy. Pharmacol Ther 153:107–124